Once-daily Prevacid 24HR is the first OTC PPI approved in its original prescription formulation.
It is the only PPI containing the active ingredient lansoprazole to be approved for OTC treatment of frequent heartburn, which is defined as heartburn that occurs two or more days per week.
The drug achieved $3.37 billion in annual sales in the US in 2008.
Novartis has licensed the Prevacid trademark and certain other intellectual property rights for OTC development and commercialization from Takeda Pharmaceuticals North America, Inc.<헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지
